ABSTRACT
BACKGROUND: Atrial fibrillation occurs in 20% to 40% of patients post cardiac surgery. Prophylactic amiodarone decreases the incidence of atrial fibrillation, especially in those not taking ß-blockers. Studies, however, vary in dosage, duration of treatment, and route of administration. Limited studies evaluating short duration use of oral amiodarone show conflicting results. We hypothesize that an order set for use of short duration, oral amiodarone started the night before surgery and continued for 4 to 6 days will decrease atrial fibrillation after heart surgery. METHODS: The Society of Thoracic Surgeons database was used to identify 471 patients who received amiodarone per order set and 151 patients that did not receive amiodarone. The amiodarone order set included amiodarone 600 mg the night before surgery and 400mg twice daily for 4 to 6 days post heart surgery. After propensity matching, 112 patients remained in each group. We compared outcomes for the 2 groups as a case-controlled, retrospective, study. RESULTS: Atrial fibrillation occurred in 43% (48 of 112) of the patients that did not receive amiodarone vs 23% (26 of 112) receiving prophylactic amiodarone (P=<.001). There was no increased incidence of hemodynamic, pulmonary, or other adverse outcomes observed between the 2 groups. CONCLUSIONS: This practical order set for, short duration, oral amiodarone, with or without adjunct ß-blocker therapy started the night before heart surgery and continued for up to six days post surgery, appears to be a safe and effective treatment for reducing the incidence of atrial fibrillation following heart surgery.
Subject(s)
Amiodarone/administration & dosage , Atrial Fibrillation/epidemiology , Atrial Fibrillation/prevention & control , Cardiac Surgical Procedures/statistics & numerical data , Postoperative Complications/epidemiology , Postoperative Complications/prevention & control , Premedication/statistics & numerical data , Administration, Oral , Female , Humans , Male , Middle Aged , Postoperative Complications/diagnosis , Prevalence , Risk Factors , Treatment Outcome , West Virginia/epidemiologySubject(s)
Diphosphonates/adverse effects , Femoral Fractures/etiology , Hip Fractures/etiology , Age Factors , Aged , Aged, 80 and over , Diphosphonates/administration & dosage , Drug Administration Schedule , Female , Femoral Fractures/epidemiology , Hip Fractures/epidemiology , Humans , Reproducibility of Results , Risk FactorsABSTRACT
Several cases have been reported of unusual spontaneous fractures with minimal trauma in the subtrochanteric and diaphyseal areas of the femur linked to long-term bisphosphonate use. After encountering three such patients, we conducted a review of published cases. The average age of these individuals were 68 years and approximately 25% had received concomitant glucocorticoids. Histomorphometric bone biopsy studies performed in some individuals have suggested that severe suppression of bone turnover may be the underlying cause; however, cause and effect has not been firmly established. Moreover, population studies have found this type of fracture rare and not increased in patients who have received bisphosphonate treatment. Physicians should continue to use bisphosphonate agents as a primary treatment for osteoporosis.
